From 31 May till 4 June 2024: HIGHLIGHTS FROM ASCO
Your direct line with Chicago
The American Society of Clinical Oncology (ASCO) 2024 brings together leading experts in the different fields of cancer from around the world. And, as usual, they gather together in Chicago, USA. The MediMix team is also onsite, and will – together with your Belgian colleagues – keep you posted about the hottest topics as they happen. And, we dive into posters and hot topics with the experts as they are being presented.
Stay tuned, and get ready for an exciting and informative journey!
With the educational support of:
In the spotlight:
The B.J. Kennedy Geriatric Oncology Award
MediMix is pleased to acknowledge Professor Hans Wildiers from the University Hospital of Leuven for his exceptional achievements in the area of geriatric oncology.
Cindy Kenis, a Nurse Specialist in Geriatric Oncology at the University Hospital of Leuven, presented at ASCO the results of the G-oncoCOACH study during the oral abstract session of the
Highlights from the Clinical Science Symposium
Dr Emiel De Jaeghere selected three interesting highlights from the clinical science symposium on the role of the microbiome in immune checkpoint inhibitor response and resistance. He discussed the potential
ASCO 2024 Plenary session
We are excited to share exclusive insights from the ASCO 2024 Plenary session, featuring discussions and results from four pivotal studies. Our experts delve into the implications of these findings for clinical practice. Watch the videos to stay updated on the latest advancements in oncology research.
Despite significant advancements in treatments for lung cancer, many patients still face challenging side effects, including anxiety, depression, and overall declines in quality of life. Recognising the need for comprehensive care, the American Society
Over the last decades, therapeutic advances for patients with limited-stage small-cell lung cancer (LS-SCLC) have been limited. With the current standard of care (i.e., concurrent chemoradiotherapy [cCRT]), the prognosis for these patients is poor
Based on the results of the phase III PACIFIC trial, consolidation therapy with durvalumab has become the standard of care for patients with unresectable stage III NSCLC who did not suffer disease progression under
Prof Dr Christian Blank, a medical oncologist at the Netherlands Cancer Institute, presented the first data from the NADINA trial at the ASCO 2024 plenary session.
This investigator-initiated trial compared neo-adjuvant ipilimumab plus nivolumab
Prof Dr Jeroen Dekervel from UZ Leuven (Belgium) and Prof Dr Florian Lordick from the University of Leipzig (Germany) discuss the ESOPEC trial.
The ESOPEC trial focused on patients with adenocarcinoma of the
Latest daily highlights
Dr Marika Rasschaert, a medical oncologist at the University Hospital Antwerp, Belgium, provided a comprehensive overview of critical studies presented at ASCO 2024 in the oral abstract session on Head
Dr Lizza Hendriks, a respiratory oncologist at the Maastricht University Medical Center (Netherlands), highlights four significant presentations on NSCLC from ASCO 2024 relevant to clinical practice.
A noteworthy presentation at
Dr Willem Lybaert, a medical oncologist at the VITAZ Sint-Niklaas & University Hospital Antwerp gives a nice summary of the oral abstract session on gastroesophageal, pancreatic and hepatobiliary tumours from
Dr Luca Arecco, a medical oncologist at the University of Genova (Italy) and the Institut Jules Bordet (Belgium), presents four trials from the oral abstract session on the adjuvant early
Prof Dr Jean-François Baurain, a medical oncologist at the Cliniques Universitaires Saint-Luc, Brussels presents an update on advanced melanoma from ASCO.
An updated analysis of the RELATIVITY-047 trial, which compared
Prof Dr Christine Gennigens, a medical oncologist at the University Hospital of CHU de Liège, Belgium, summarised the “Stronger Together: Novel Combinations Across the Gynaecological Cancer Spectrum” session at ASCO
Dr Jérémy Blanc, a medical oncologist in training from the Institut Jules Bordet in Brussels, shares the latest information regarding biomarkers in RCC from the oral abstract session at ASCO
Prof Hans Prenen, a medical oncologist at the University Hospital Antwerp, Belgium, provided a comprehensive overview of critical studies presented at ASCO 2024 in the rapid oral abstract session on
Prof Hannelore Denys, a medical oncologist at the University Hospital Ghent, Belgium, provided a comprehensive overview of critical studies presented at ASCO 2024 in the Gynaecological Cancers session.
The BrUOG
Prof Dr Piet Dirix, a radiation oncologist at the Iridium Network in Antwerp, highlights the most interesting presentations from the oral abstract session on prostate, testicular, and penile cancer.
The
Dr Charlotte De Bondt, thoracic oncologist at GZA Hospitals, Antwerp presents her selection of highlights from the rapid oral abstract session on lung cancer. Dr Jonathan Spicer presented a four-year
Dr Iris Dirven, medical oncologist in training at the University Hospital of Brussels discussed her selection from the rapid oral abstract session on melanoma/skin cancer.
The NADOM trial investigated the
Dr Laure-Anne Teuwen, a medical oncologist at the University Hospital of Antwerp in Belgium, reports on four presentations from the 2024 ASCO conference’s rapid oral session on metastatic breast cancer.<br
Dr Willem Lybaert, medical oncologist at VITAZ Sint-Niklaas and University Hospital Antwerp, presents highlights from the rapid oral abstract session on head & neck cancer. The phase 1 TARGET-HPV trial
Dr Marika Rasschaert, a medical oncologist at the University Hospital Antwerp, Belgium, provided a comprehensive overview of critical studies presented at ASCO 2024 in the Central Nervous System Tumours session.
Prof Dr Jean-François Baurain, a medical oncologist at the Cliniques Universitaires Saint-Luc, Brussels presents a first selection of interesting highlights in melanoma and skin cancer.
The COMBI-AD study assessed adjuvant
Prof. Alain Hendlisz, a digestive oncologist at the Institut Jules Bordet in Brussels, Belgium, provided a comprehensive overview of key studies presented at ASCO 2024 in the rapid oral abstract
Prof Dr François Duhoux, a medical oncologist at the Cliniques Universitaires Saint-Luc (Belgium), discusses the most remarkable presentations on metastatic breast cancer from ASCO 2024.
The first trial is the
Dr Jérémy Blanc, medical oncologist in training from the Institut Jules Bordet, Brussels selected highlights on bladder cancer from ASCO24. Dr Jae-Lyun Lee presented the first results from the
Prof Eric Van Cutsem, a digestive oncologist at University Hospitals, Belgium, provided a comprehensive overview of key studies presented at ASCO 2024 in the session on colorectal and anal cancer.
Dr Dieter Stevens, a thoracic oncologist at University Hospitals Gent in Belgium, shares key findings from ASCO2024 on advanced or metastatic NSCLC patients with rare oncogenic alterations.
Dr Elisa Agostinetto, a medical oncologist and research fellow at Institut Jules Bordet in Brussels, Belgium, provides a comprehensive overview of five selected abstracts presented at ASCO 2024 during the
Prof Piet Dirix, radiation oncologist at the Iridium Network in Antwerp highlights the most interesting presentations from the oral abstract session on prostate cancer (PCa). Extensive preclinical data suggest that
Prof Dr Christophe Dooms, a respiratory oncologist at the University Hospitals Leuven (Belgium), highlights three significant presentations on mNSCLC from ASCO 2024 relevant to clinical practice. The first trial, NRG-LU002,